|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114,000.00 KRW | -4.36% |
|
-6.86% | -8.51% |
| Jan. 11 | SK Biopharmaceuticals Secures FDA Approval for New Drug Testing | MT |
| Dec. 29 | IT Chem Wins Drug Consignment Production Deal from SK Biotek | MT |
| Capitalization | 8,928B 6.05B 5.15B 4.77B 4.49B 8.36B 550B 8.97B 55.11B 21.77B 262B 22.67B 22.21B 955B | P/E ratio 2025 * |
51x | P/E ratio 2026 * | 33.6x |
|---|---|---|---|---|---|
| Enterprise value | 8.63B 5.85M 4.98M 4.62M 4.34M 8.08M 532M 8.67M 53.3M 21.06M 253M 21.93M 21.48M 923M | EV / Sales 2025 * |
12.1x | EV / Sales 2026 * | 9.38x |
| Free-Float |
35.81% | Yield 2025 * |
-
| Yield 2026 * | 0.09% |
| 1 day | -4.36% | ||
| 1 week | -6.86% | ||
| Current month | -8.51% | ||
| 1 month | -11.56% | ||
| 3 months | +11.22% | ||
| 6 months | +10.68% | ||
| Current year | -8.51% |
| 1 week | 112,100 |  | 122,600 |
| 1 month | 112,100 | | 131,700 |
| Current year | 112,100 | | 127,900 |
| 1 year | 86,900 | | 144,100 |
| 3 years | 57,600 | | 144,100 |
| 5 years | 50,900 | | 155,000 |
| 10 years | 50,900 | | 269,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong-Hoon Lee
CEO | Chief Executive Officer | 58 | 2022-12-31 |
Ji-Young Jeong
DFI | Director of Finance/CFO | 53 | - |
Chang-Ho Yu
PRN | Corporate Officer/Principal | 51 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hae-Young Ahn
BRD | Director/Board Member | 69 | 2019-08-26 |
Min-Seop Song
BRD | Director/Board Member | 56 | 2019-08-26 |
Min-Ji Kim
BRD | Director/Board Member | 54 | 2023-03-27 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +6.00% | 0.08% | 20 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.36% | -6.86% | +4.88% | +59.00% | 6.32B | |
| -1.15% | -2.28% | -14.00% | -35.60% | 64.05B | |
| +0.23% | +1.35% | +13.03% | -9.21% | 8.58B | |
| +1.72% | -1.77% | +28.11% | +39.37% | 8.28B | |
| -4.28% | -7.72% | -21.65% | +102.13% | 5.43B | |
| +0.35% | -1.46% | +170.97% | +39.54% | 4.11B | |
| +1.01% | -4.43% | -12.69% | -20.57% | 2.92B | |
| -0.29% | -3.90% | +29.03% | +20.88% | 2.86B | |
| +1.65% | +10.59% | +62.13% | +51.32% | 2.88B | |
| Average | -0.55% | -1.56% | +28.87% | +27.43% | 11.71B | |
| Weighted average by Cap. | -0.89% | -2.17% | +2.75% | -7.54% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 711B 481M 410M 380M 358M 666M 43.82B 714M 4.39B 1.73B 20.84B 1.81B 1.77B 76.04B | 901B 610M 520M 482M 453M 843M 55.5B 904M 5.56B 2.2B 26.39B 2.29B 2.24B 96.31B |
| Net income | 175B 118M 101M 93.32M 87.77M 163M 10.76B 175M 1.08B 426M 5.11B 443M 434M 18.66B | 266B 180M 153M 142M 134M 249M 16.37B 267M 1.64B 648M 7.79B 675M 661M 28.41B |
| Net Debt | -294B -199M -170M -157M -148M -275M -18.12B -295M -1.81B -717M -8.61B -746M -731M -31.44B | -477B -323M -275M -255M -240M -447M -29.42B -479M -2.95B -1.16B -13.99B -1.21B -1.19B -51.05B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-20 | 114,000.00 ₩ | -4.36% | 330,580 |
| 26-01-20 | 119,200.00 ₩ | +0.85% | 191,695 |
| 26-01-19 | 118,200.00 ₩ | -1.83% | 277,252 |
| 26-01-16 | 120,400.00 ₩ | +0.67% | 273,982 |
| 26-01-15 | 119,600.00 ₩ | -1.48% | 241,857 |
End-of-day quote Korea S.E., January 20, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A326030 Stock
Select your edition
All financial news and data tailored to specific country editions
